Dimethyl Sulfoxide

CAS RN:67-68-5

Health Effects

0.2.1 SUMMARY OF EXPOSURE
  • 0.2.1.1 ACUTE EXPOSURE
    • A) WITH THERAPEUTIC USE
      • 1) DMSO has shown very few toxic symptoms in humans. The most common are nausea, skin rashes, headache, and an unusual garlic-onion-oyster smell in body and breath.
      • 2) DMSO is a skin, eye, and respiratory tract irritant. It may cause skin irritation and reddening if spilled on clothing and allowed to remain. DMSO readily penetrates the skin and may carry other dissolved chemicals into the body.
      • 3) DMSO may cause urticaria and, rarely, anaphylaxis.
      • 4) DMSO is an experimental teratogen and also causes other reproductive effects in experimental animals. It is also a questionable carcinogen with experimental tumorigenic data.
0.2.3 VITAL SIGNS0.2.4 HEENT
  • 0.2.4.1 ACUTE EXPOSURE
    • A) WITH THERAPEUTIC USE
      • 1) Dry throat, mouth, and nasal passages are possible with prolonged use.
    • B) WITH POISONING/EXPOSURE
      • 1) Transient photophobia and color vision disturbances have been reported.
      • 2) ANIMAL STUDIES - The lenticular changes causing myopia seen in animals following chronic use have not yet been reported in humans.
0.2.6 RESPIRATORY
  • 0.2.6.1 ACUTE EXPOSURE
    • A) WITH THERAPEUTIC USE
      • 1) The unusual oyster breath is a common finding. Dyspnea and increased symptoms of bronchial asthma are possible.
0.2.7 NEUROLOGIC
  • 0.2.7.1 ACUTE EXPOSURE
    • A) WITH THERAPEUTIC USE
      • 1) Headache, dizziness, and sedation have been seen.
0.2.8 GASTROINTESTINAL
  • 0.2.8.1 ACUTE EXPOSURE
    • A) WITH THERAPEUTIC USE
      • 1) Nausea, vomiting, diarrhea, anorexia and constipation may occur.
0.2.9 HEPATIC
  • 0.2.9.1 ACUTE EXPOSURE
    • A) WITH THERAPEUTIC USE
      • 1) Elevated liver enzymes have been reported, and two questionable cases of liver toxicity have been reported.
0.2.10 GENITOURINARY
  • 0.2.10.1 ACUTE EXPOSURE
    • A) WITH THERAPEUTIC USE
      • 1) A dose dependent hematuria is possible.
0.2.13 HEMATOLOGIC
  • 0.2.13.1 ACUTE EXPOSURE
    • A) WITH THERAPEUTIC USE
      • 1) Possible eosinophilia has been reported, and when given IV, hemolysis and increased serum osmolality has been reported.
0.2.14 DERMATOLOGIC
  • 0.2.14.1 ACUTE EXPOSURE
    • A) WITH THERAPEUTIC USE
      • 1) Stinging and burning of the skin as well as rashes and vesicles have been seen. A heat reaction may occur if administered on wet skin. Systemic contact dermatitis has occurred from intravesical administration.
0.2.19 IMMUNOLOGIC
  • 0.2.19.1 ACUTE EXPOSURE
    • A) WITH THERAPEUTIC USE
      • 1) DMSO releases histamine from mast cells.
0.2.20 REPRODUCTIVE HAZARDS
  • A) Data for humans are lacking. Teratogenic effects have been seen in animals. permatozoa of honey bees frozen with DMSO as the cryoprotectant produced total sterility in 3% of the female progeny. Total sterility is very rare in honey bees.
0.2.21 CARCINOGENICITY
  • 0.2.21.1 IARC CATEGORY
    • A) IARC Carcinogenicity Ratings for CAS67-68-5 (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004):
      • 1) Not Listed
0.2.22 GENOTOXICITY
  • A) DMSO tested positive for mutagenicity in bacteria and caused DNA damage in a mouse model (RTECS , 1991).
Find more information on this substance at: Hazardous Substances Data Bank , TOXNET , PubMed